Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV000863934 | SCV001004670 | likely benign | Bardet-Biedl syndrome | 2024-01-29 | criteria provided, single submitter | clinical testing | |
Illumina Laboratory Services, |
RCV001112170 | SCV001269806 | uncertain significance | Bardet-Biedl syndrome 10 | 2017-04-28 | criteria provided, single submitter | clinical testing | This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). Publications were found based on this search. However, the evidence from the literature, in combination with allele frequency data from public databases where available, was not sufficient to rule this variant in or out of causing disease. Therefore, this variant is classified as a variant of unknown significance. |
New York Genome Center | RCV001112170 | SCV004046500 | uncertain significance | Bardet-Biedl syndrome 10 | 2023-01-26 | criteria provided, single submitter | clinical testing | |
Prevention |
RCV003928362 | SCV004738064 | likely benign | BBS10-related condition | 2020-10-30 | criteria provided, single submitter | clinical testing | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |
Department of Pathology and Laboratory Medicine, |
RCV001355061 | SCV001549827 | uncertain significance | not provided | no assertion criteria provided | clinical testing | The BBS10 p.R530S variant was identified in the literature in 1 of 132 patients with Bardet Biedl syndrome who also carried a BBS12 p.V503M variant (Janssen_2011_PMID:21052717). The variant was identified in dbSNP (ID: rs146812823) and ClinVar (classified as likely benign by Invitae). The variant was identified in control databases in 32 of 282760 chromosomes at a frequency of 0.0001132 (Genome Aggregation Database March 6, 2019, v2.1.1). The variant was observed in the following populations: Ashkenazi Jewish in 26 of 10368 chromosomes (freq: 0.002508), South Asian in 1 of 30610 chromosomes (freq: 0.000033), European (non-Finnish) in 4 of 129080 chromosomes (freq: 0.000031) and Latino in 1 of 35438 chromosomes (freq: 0.000028), but was not observed in the African, East Asian, European (Finnish), or Other populations. The p.R530 residue is not conserved in mammals and computational analyses (PolyPhen-2, SIFT, MutationTaster, Revel, FATHMM, MetaLR, DANN) do not suggest a high likelihood of impact to the protein; however, this information is not predictive enough to rule out pathogenicity. The variant occurs outside of the splicing consensus sequence and in silico or computational prediction software programs (Splice AI exome) do not predict a difference in splicing. In summary, based on the above information the clinical significance of this variant cannot be determined with certainty at this time. This variant is classified as a variant of uncertain significance. | |
Natera, |
RCV001112170 | SCV002091756 | likely benign | Bardet-Biedl syndrome 10 | 2020-01-24 | no assertion criteria provided | clinical testing |